At a glance
ClinicalIndex Comparison Record- ✓Treated or untreated stage I hypertension
- ✕Diabetes mellitus
- ✕Renal impairment (serum creatinine >1.4 mg/dL)
- ✕Heart disease including congestive heart failure, sustained arrhythmia, or coronary heart disease
- ✕Chronic regular NSAID use
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Preventing Metabolic Side Effects of Thiazide Diuretics With KMgCitrate
In Brief
A clinical study evaluating Potassium Magnesium Citrate (KMgCit), Potassium Chloride (KCl), and 1 other intervention for Hypertension. Completed, enrolled 61 participants across 3 sites.
Detailed Summary
Chlorthalidone (CTD) may produce various metabolic disturbances, including hypokalemia, activation of Renin-Angiotensin- Aldosterone (RAA) system, oxidative stress, dyslipidemia, Fibroblast growth factor 23 (FGF23) synthesis, and magnesium depletion. These factors may interact with each other to contribute to the development of insulin resistances and metabolic syndrome. Smaller studies have suggested that Potassium magnesium Citrate (KMgCit) can ameliorate CTD- induced metabolic side effects independent of correction of hypokalemia. This study will tests if KMgCit ameliorates CTD induced metabolic effects independent of correction of hypokalemia.
Study Details
Timeline
Interventions
KMgCit will be administer for 4 months with chlorthalidone.
KCl will be administer for 4 months with chlorthalidone.
Chlorthalidone will be administered for 2-3 weeks. Then either KCL or KMgCit will be added to Chlorthalidone and the combination will be taken for 4 months.